BioCentury | Sep 16, 2020
Management Tracks

O’Brien to lead Tizona in wake of Gilead deal; plus Silence, PacBio, Rhythm

...the CEO post at Trishula Therapeutics last month (see “Gilead Places Latest Bet on Cancer Immunosuppression”).siRNA...
BioCentury | Sep 10, 2020
Finance

Korro Bio’s $91.5M series A brings in new investors, launches hunt for CEO

...Bermingham told BioCentury. Bermingham is president and CEO of Triplet Therapeutics Inc., which is developing antisense and siRNA...
BioCentury | Aug 27, 2020
Distillery Therapeutics

siRNAs against plaque-destabilizing molecule CAMK2G for atherosclerosis

...treat atherosclerosis. The nanoparticles consist of a poly(lactic-co-glycolic acid) (PLGA) core loaded with an anti-CAMK2G siRNA-cationic...
...and enhanced collagen cap thickness, a marker of plaque stability. Next steps include applying the siRNA-loaded...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Targeting the PP2A-STRN3 interaction to treat gastric cancer

DISEASE CATEGORY: Cancer INDICATION: Gastric cancer Interrupting the interaction between PP2A catalytic subunit PPP2CA and STRN3, a regulatory subunit, could treat gastric cancer. In patients, STRN3 expression...
BioCentury | Aug 26, 2020
Finance

Partnerships paved the way to a Tokyo IPO for Modalis

...the missing gene into the cell” and siRNA...
BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

...plc (LSE:SLN) proposed to raise up to $314.9 million via a listing on NASDAQ. The siRNA...
BioCentury | Aug 25, 2020
Finance

Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

...on cardiovascular outcomes. That is the likely path for another therapy as well: inclisiran, a PCSK9-targeted siRNA...
BioCentury | Aug 14, 2020
Translation in Brief

Hesperos applies organ-on-a-chip tech to ALS, Sinopharm details interim COVID-19 vaccine readout and more

...In two mouse models of kidney disease, siRNA-mediated...
BioCentury | Aug 7, 2020
Management Tracks

Greene, an architect of Alnylam, looks to the next chapter

...Roche (SIX:ROG; OTCQX:RHHBY) in 2007. With a strong IP portfolio -- including 150 patents covering siRNA...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Vesicular trafficking protein fusion targets for metastatic osteosarcoma

...the inverted DOK5 intron sequences inhibited migration and invasion. Polyethylene glycol-grafted polyethyleneimine nanoparticles bearing an siRNA...
Items per page:
1 - 10 of 1781
BioCentury | Sep 16, 2020
Management Tracks

O’Brien to lead Tizona in wake of Gilead deal; plus Silence, PacBio, Rhythm

...the CEO post at Trishula Therapeutics last month (see “Gilead Places Latest Bet on Cancer Immunosuppression”).siRNA...
BioCentury | Sep 10, 2020
Finance

Korro Bio’s $91.5M series A brings in new investors, launches hunt for CEO

...Bermingham told BioCentury. Bermingham is president and CEO of Triplet Therapeutics Inc., which is developing antisense and siRNA...
BioCentury | Aug 27, 2020
Distillery Therapeutics

siRNAs against plaque-destabilizing molecule CAMK2G for atherosclerosis

...treat atherosclerosis. The nanoparticles consist of a poly(lactic-co-glycolic acid) (PLGA) core loaded with an anti-CAMK2G siRNA-cationic...
...and enhanced collagen cap thickness, a marker of plaque stability. Next steps include applying the siRNA-loaded...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Targeting the PP2A-STRN3 interaction to treat gastric cancer

DISEASE CATEGORY: Cancer INDICATION: Gastric cancer Interrupting the interaction between PP2A catalytic subunit PPP2CA and STRN3, a regulatory subunit, could treat gastric cancer. In patients, STRN3 expression...
BioCentury | Aug 26, 2020
Finance

Partnerships paved the way to a Tokyo IPO for Modalis

...the missing gene into the cell” and siRNA...
BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

...plc (LSE:SLN) proposed to raise up to $314.9 million via a listing on NASDAQ. The siRNA...
BioCentury | Aug 25, 2020
Finance

Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

...on cardiovascular outcomes. That is the likely path for another therapy as well: inclisiran, a PCSK9-targeted siRNA...
BioCentury | Aug 14, 2020
Translation in Brief

Hesperos applies organ-on-a-chip tech to ALS, Sinopharm details interim COVID-19 vaccine readout and more

...In two mouse models of kidney disease, siRNA-mediated...
BioCentury | Aug 7, 2020
Management Tracks

Greene, an architect of Alnylam, looks to the next chapter

...Roche (SIX:ROG; OTCQX:RHHBY) in 2007. With a strong IP portfolio -- including 150 patents covering siRNA...
BioCentury | Jul 31, 2020
Distillery Therapeutics

Vesicular trafficking protein fusion targets for metastatic osteosarcoma

...the inverted DOK5 intron sequences inhibited migration and invasion. Polyethylene glycol-grafted polyethyleneimine nanoparticles bearing an siRNA...
Items per page:
1 - 10 of 1781